Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
–News Direct–
Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with news the company has received a Notice of Allowance from the US Patent and Trademark Office for a new patent application, marking a significant step in the company's intellectual property (IP) strategy.
This latest patent is distinct from two others granted last year, focusing on the composition of matter protecting a specific polymorph of vidofludimus calcium. The company aims to ensure broad protection and exclusivity for vidofludimus calcium, especially as it approaches the final development stage.
Vitt highlighted Immunic's global patent strategy, aiming to cover all important territories and build multiple protection layers around their inventions. The strategy includes secu...